Clinical-epidemiological characterization in patients diagnosed with immune thrombocytopenic purpura at “Vladimir Ilich Lenin” General Hospital
Keywords:
Autoimmunity, Bleeding, Thrombocytopenia, Thrombocytopenic purpura.Abstract
Introduction: immune thrombocytopenic purpura is a bleeding disorder characterized by an isolated decrease in platelets, not associated with another recognizable pathology. The management of immune thrombocytopenia is a matter of discussion regarding its evolution, diagnosis, prognosis and treatment.
Objective: to characterize clinically-epidemiologically the patients diagnosed with immune thrombocytopenic purpura at the Vladimir Lenin General Hospital, in the period from 2015 to 2020.
Method: an observational, descriptive cross-sectional study was carried out at the “Vladimir Lenin” General Hospital, of the province Holguín, Cuba. The study period ranged from 2015 to 2020. The universe consisted of 30 patients who met the inclusion criteria of the research. It worked with the entire universe.
Results: the female sex (63.3%) and the age group from 40 to 49 years (46.7%) predominated. At the time of admission, 43.3% of the patients studied presented slight bleeding and 46.7% a platelet count with moderate thrombocytopenia. 56.7% had a complete response to first-line treatment.
Conclusions:there was a predominance of female patients, between the ages of 40 to 49 years, with mild bleeding and moderate thrombocytopenia at the time of admission. The largest number of patients had a complete response to first-line treatment and progressed to chronicity.
References
2. Beligoy LE. Trombocitopenia inmune persistente y crónica del adulto: opciones terapéuticas. Rev Hematología [Internet]. 2018 [citado 31/08/2021]; 22(ext):54-61. Disponible en: http://revistahematologia.com.ar/index.php/Revista/article/view/56/43
3. Arepally GM. Heparin-induced thrombocytopenia. Arterioscler Thromb Vasc Biol [Internet]. 2021 [citado 31/08/2021]; 41:141-152. Disponible en: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.120.315445
4. Terrell DR, Neunert CE, Cooper N, Heitink-Pollé KM, Kruse C, Imbach P, et al. Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Kaunas) [Internet]. 2020 [citado 31/08/2021]; 56(12):667. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761470/
5. Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kühne T, et al. Immune Thrombocytopenia – Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat [Internet]. 2018 [citado 31/08/2021]; 41(suppl5):1–30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30235458/ https://www.karger.com/Article/Pdf/492187
6. López Rivera VE. Púrpura Trombocitopénica inmune: Respuesta al tratamiento con Metilprednisolona en pacientes que ingresaron al Hospital Manuel de Jesús Rivera “La Mascota” en el período 01 de Enero 2014 al 31 de Diciembre del 2016. [Tesis]. [Internet]. Nicaragua: Universidad Nacional Autónoma de Nicaragua. Facultad De Ciencias Médicas UNAN Managua; 2017. [citado 31/08/2021]. Disponible en: https://repositorio.unan.edu.ni/8162/1/98676.pdf
7. Silva CL, Grando AC. Complications of idiopathic thrombocytopenic purpura in pregnancy: a review of literature. J Bras Patol Med Lab [Internet]. 2021 [citado 31/08/2021]; 57(1):1-8. Disponible en: https://www.scielo.br/j/jbpml/a/BGbTfj3hBHbVTt3zgFxbBmt/#
8. Donato H. PTI. “Según pasan los años”. Rev Hematología [Internet]. 2017 [citado 31 31/08/2021]; 21(ext23):137–51. Disponible en: http://www.sah.org.ar/revista/numeros/vol21/extra3/21-vol21-extra_noviembre.pdf
9. León Mondragón EK, Pereyra Ramírez JG. Características clínicas, laboratoriales y evolución de trombocitopenia inmune en pacientes adultos atendidos en Hospital Regional Lambayeque y Hospital Docente Las Mercedes, 2013 – 2017. [Tesis]. [Internet]. Perú: Universidad Nacional “Pedro Ruiz Gallo”. Facultad de Medicina Humana; 2019 [citado 31/08/2021]. Disponible en: https://repositorio.unprg.edu.pe/handle/20.500.12893/3883
10. Nina García NM, Huarita H. Púrpura Trombocitopénica Idiopática en adultos: experiencia en un hospital de tercer nivel, La Paz, Bolivia. Rev Cient Cienc Méd [Internet]. 2019 [citado 31/08/2021]; 22(2):7-14. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1817-74332019000200002&lng=es
11. Donato H, Bacciedoni V, Rapetti MC, Elena G, Lavergne M, Rossi N, et al. Trombocitopenia inmune. Guía de diagnóstico y tratamiento. Arch Argent Pediatr [Internet]. 2019 [citado 31/08/2021]; 117(supl6):243-254. Disponible en: https://www.sap.org.ar/uploads/consensos/consensos_trombocitopenia-inmune-guia-de-diagnostico-y-tratamiento-91.pdf
12. Onisâi M, Vlădăreanu Am, Spînu A, Găman M, Bumbea H. Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease. ROM J INTERN MED [Internet]. 2019 [citado 31/08/2021]; 57(4):273-283. Disponible en: https://sciendo.com/pdf/10.2478/rjim-2019-0014
13. Palmezano Díaz JM, Figueroa Pineda CL, Rodríguez Amaya RM, Plazas Rey LK. Prevalencia y caracterización de las enfermedades autoinmunitarias en pacientes mayores de 13 años en un hospital de Colombia. Med Interna Méx [Internet]. 2018 [citado 31/08/2021]; 34(4):522-535. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-48662018000400003&lng=es
14. Palmezano Diaz JM, Figueroa Pineda CL, Amaya RM, Rengifo Quintero LJ, Mogollón Moreno YD, Moreno Useche LD, et al. Caracterización Clínica de los Pacientes con Púrpura Trombocitopénica Inmune en un Hospital Universitario en Colombia. Rev Med [Internet]. 2018 [citado 31/08/2021]; 40(1):108-109. Disponible en: https://revistamedicina.net/ojsanm/index.php/Medicina/article/view/1299
15. Petro López K, Sgromo M, Boedo L, Mandrile A, Almeida L. Púrpura trombocitopénica inmune: tratamiento de segunda línea, experiencia en el Sanatorio Güemes centrada en trombomiméticos. Rev Hematología [Internet]. 2020 [citado 31/08/2021]; 24(3):19-24. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7863748
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal, accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of your work, which will be under a Creative license Commons Attribution-NonCommercial-ShareAlike 4.0 International . (CC BY-NC-SA 4.0).
The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (eg:deposit it in an institutional telemat
